All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

Merck & Co.'s KEYTRUDA (pembrolizumab) wins European Commission approval for resectable locally advanced head and neck squamous cell carcinoma
Antibody, cancer, monoclonal antibody, head and neck squamous cell carcinoma, PD-1 inhibitor, combination therapy - Read more

THE GOOD
Business Development & Partnerships

Regeneron, ModeX partner on multispecific antibodies, $7M upfront, over $1B total deal value
Licensing deal, antibody, oncology, milestone payments, multispecific therapeutics - Read more

Eli Lilly, Walmart partner to expand Zepbound obesity shot access through retail pharmacy pickup
Commercial partnership, obesity, retail distribution, cash payments - Read more

Rosa & Co., PhenoVista partner to advance cell-based assays with PhysioPD modeling platform
Research collaboration, drug discovery, quantitative systems pharmacology, mechanistic modeling - Read more

IASO Biotherapeutics, GC Cell partner on CAR-T therapy Fucaso commercialization in South Korea
Commercialization agreement, oncology, cell therapy, CAR-T - Read more

Samsung Bioepis purchases BYOOVIZ biosimilar commercial rights in Europe from Biogen
Asset purchase agreement, ophthalmology, biosimilar, commercialization - Read more

Roche exercises option in Recursion deal for brain immune cell genome mapping, $30M payment
Licensing deal, neurological, milestone payments, AI/ML - Read more

PRESENTED BY PROMOVEO HEALTH
Contract Sales Reps = Fast Deployment + Lower Cost

We've built 100+ pharma sales teams for companies of all sizes, and we can help you.

We build agile field teams that scale based on your needs - all with fast deployment + lower cost than full-time reps.

See how flexible can work - click here to learn more.

✅ More Good News ✅

THE GOOD
Clinical Trials

Kyverna Therapeutics' KYV-101 CAR-T therapy targeting CD19 shows promising Ph2 results in generalized myasthenia gravis
Cell therapy, autoimmune, CAR-T, generalized myasthenia gravis, CD19 target - Read more

Argenx's Vyvgart efgartigimod hits Ph3 win in seronegative generalized myasthenia gravis, seeks label expansion
Antibody, autoimmune, FcRn blocker, myasthenia gravis, seronegative patients - Read more

BridgeBio's encaleret meets Ph3 endpoints for autosomal dominant hypocalcemia Type 1 rare endocrine disorder
Small molecule, endocrine disorder, calcium-sensing receptor antagonist, autosomal dominant hypocalcemia, parathyroid hormone - Read more

Sonoma Biotherapeutics reports positive Ph1 data for SBT-77-7101 CAR-Treg therapy in refractory rheumatoid arthritis
Cell therapy, autoimmune, CAR-T regulatory T cells, rheumatoid arthritis, refractory patients - Read more

Novartis reports positive Ph3 results for ianalumab targeting BAFF receptor in Sjogren's disease treatment
Antibody, autoimmune, monoclonal antibody, Sjögren's syndrome, B cell depletion, BAFF receptor - Read more

AbbVie's Rinvoq upadacitinib meets Ph3 endpoints for non-segmental vitiligo in adults and adolescents
Small molecule, autoimmune, JAK inhibitor, vitiligo, repigmentation - Read more

THE GOOD
Company Launches

Neutrolis emerges with DNA-enzyme drug targeting immune NETs for autoimmune diseases like arthritis, lupus
Enzyme therapy, autoimmune, strategic, operational - Read more [Paywall]

THE GOOD
Earnings & Finances

GSK upholds £40B ($46.62B) 2031 sales target despite analyst skepticism in Walmsley's final CEO report
Antibody-drug conjugate, oncology, strategic, financial - Read more

THE GOOD
Fundraises

Resilience raises $825M debt financing, accelerating CDMO biomanufacturing strategy and operations
CDMO, biomanufacturing, biologics, sterile injectables, cell-based medicines - Read more

Pinetree Therapeutics raises $47M Series B, targeted protein degraders for drug-resistant cancers
Oncology, protein degradation, preclinical, targeted therapy, platform technology - Read more

Ribo Life Science seeks IPO in Hong Kong, siRNA biotech with Phase 2 programs
siRNA, clinical-stage, thrombotic diseases, hypertriglyceridemia, hepatitis - Read more

THE GOOD
Investments

Eli Lilly invests $1.2B to upgrade Puerto Rico plant for oral drug production capacity
Small molecule, cardiometabolic, operational, major transaction - Read more

THE GOOD
Market Reports

ICER raises value ceiling for Novo Nordisk and Eli Lilly obesity drugs citing expanded cardiovascular benefits
GLP-1 receptor agonist, obesity, financial, cost-effectiveness - Read more

THE GOOD
Mergers & Acquisitions

Thermo Fisher to acquire Clario for $8.9B to strengthen clinical trial data capabilities
Clinical research services, strategic, major transaction, operational - Read more

THE GOOD
Product Launches

Roche's Flatiron Health launches six blood cancer datasets covering 505,000 patient records
CAR-T, hematologic malignancies, strategic, operational - Read more

Genesis Molecular AI unveils Pearl foundation model, outperforming AlphaFold 3 in drug-protein structure prediction by 40%
AI drug discovery platform, strategic, competitive, technological advancement - Read more

THE GOOD
Regulatory

FDA proposes streamlined biosimilar approval pathway to reduce drug costs, avoid expensive clinical trials
Biosimilar, regulatory, operational, cost reduction - Read more

PRESENTED BY YOU?
Get the attention of 2300+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Clinical Trials

AbbVie halts Ph1 trial of Dragonfly's ABBV-303 c-Met-targeting NK cell engager for solid tumors
Antibody, cancer, NK cell engager, solid tumors, c-Met target - Read more

Merck & Co. and Eisai discontinue Keytruda-Lenvima Ph3 trial in hepatocellular carcinoma after overall survival miss
Antibody, cancer, PD-1 inhibitor, hepatocellular carcinoma, combination therapy - Read more

THE BAD
Earnings & Finances

GSK blames US 'macro factors' for 15% Shingrix vaccine sales decline amid broader immunization skepticism
Vaccine, infectious disease, financial, operational - Read more

THE BAD
Layoffs

Genentech conducts third layoff round this year, cutting 118 more jobs at South San Francisco headquarters
Monoclonal antibody, autoimmune, cost reduction, operational, strategic - Read more

THE BAD
Strategic Plans

GSK abandons CD226 cancer therapy programs, dropping nelistotug and anti-PVRIG antibody in strategic shift
Monoclonal antibody, oncology, strategic, cost reduction - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here